Quick read
Fair Value Engine
Decision-focused synthesis of expected stock prices combining relative peer multiples and intrinsic models.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot
NOV stock price vs RES: inconclusive
Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Price gap
N/A
Coverage
Medium · 60%
Free account · revisit it from your workspace
Quick read
Decision-focused synthesis of expected stock prices combining relative peer multiples and intrinsic models.
Metric-by-metric
Filter, sort, and scan where each company leads, where gaps are small, and where comparisons are not meaningful.
| Metric | NOV | RES | Spread |
|---|---|---|---|
Revenue growth (YoY) FY 2024 -> FY 2025 | -1.4% | 15.0% | RES leads by 109.5% Higher Revenue growth |
Gross margin | 20.2% | 24.2% | RES leads by 16.5% Higher Gross margin |
EBITDA margin | 10.3% | 13.5% | RES leads by 24.1% Higher EBITDA margin |
EV/Revenue | N/M | N/M | Insufficient data No additional context |
P/E | N/M | N/M | Not comparable Not comparable |
Net debt / EBITDA | 0.2 | -0.9 | RES leads by 125.2% Lower Net debt / EBITDA |
Statements
Core income statement and balance sheet metrics aligned to the reporting windows.
| Metric | NOV | Delta vs RES | RES |
|---|---|---|---|
| Revenue | $8.74B | 437.6% higher | $1.63B |
| Gross profit | $1.77B | 348.8% higher | $393.68M |
| Operating income | $494.00M | 1004.4% higher | $44.73M |
| EBITDA | $897.00M | 308.2% higher | $219.77M |
| Net income | $145.00M | 352.0% higher | $32.08M |
| EPS | 0.4 | 160.0% higher | 0.1 |
| Revenue growth | -1.4% | 109.5% lower | 15.0% |
| Gross margin | 20.2% | 16.5% lower | 24.2% |
| Operating margin | 5.6% | 105.4% higher | 2.8% |
| EBITDA margin | 10.3% | 24.1% lower | 13.5% |
| Net margin | 1.7% | 15.9% lower | 2.0% |
Trendline
Track multi-year revenue, earnings, and margin direction before underwriting a rerating.
Price framework
Market cap + debt - cash, shown for the current pair and benchmark median context.
Price framework
Baseline discounted cash flow model estimating total intrinsic firm value first, then bridging to an implied stock price per share.
Risk control
Financial health checks to separate durable balance sheets from potential value traps.
Comparable set
Place both companies in context relative to a wider comparable universe.
LLM-powered Synthesis
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
NOV screens as expensive versus both RES-based and DCF indications, but its superior operating scale and ROIC partly offset the valuation gap despite weaker growth and lower margins than RES.
If you believe NOV can reaccelerate revenue growth and sustain margin expansion, then holding or adding may be reasonable because the current premium valuation already discounts stronger earnings delivery; otherwise, the data favors caution because NOV trades above the P/E-implied value and above the DCF range.
NOV's current price of $19.54 sits above the $15.11 implied price from the P/E-based valuation, implying 22.7% downside. Versus the broader valuation references, NOV is above the DCF range of $10.58-$14.32 and only modestly within the historical band of $17.59-$21.49.
Supporting Metrics